Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 3CNS 3NET 2Head & Neck 1

Conditions

Neuroendocrine Tumors 3Parkinson Disease 2Neuroblastoma 2Congenital Hyperinsulinism 2Lewy Body Disease 1Brain Neoplasms 1

Interventions

gallium Ga 68 dotatate 4fluorodopa F 18 2Magnetic Resonance Spectroscopy 2pertuzumab 1pentetreotide 1olaparib 1lutetium Lu 177 dotatate 1arginyllysine 1Whole Body Imaging 1Tretinoin 1Nivolumab 1Isotretinoin 1Furosemide 1Erlotinib Hydrochloride 1Amino Acids 190Y-octreotide, DOTA-Tyr(3)- 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 13-fluorobenzylguanidine 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroblastoma × fluorodopa F 18 × NET × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT03042416 2022-01-10

18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety

University of Alberta

Phase 3 Completed
400 enrolled
CNSEndocrineNET

Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡